Conferences
ASCO GU 2025: Real-World Comparison of Cabazitaxel vs. 177-Lutetium-PSMA Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer
February 14, 2025
ASCO GU 2025: Expanded Access Program of Cretostimogene Grenadenorepvec in Patients with NMIBC Unresponsive to BCG
February 14, 2025
ASCO GU 2025: Final Overall Survival with Talazoparib + Enzalutamide as First-line Treatment in Patients with HRR-deficient mCRPC in the Phase 3 TALAPRO-2 Trial
February 14, 2025
ASCO GU 2025: Effectiveness and Safety of Radium-223 in Men with mCRPC: A Systematic Literature Review of 48 Real-world Studies
February 14, 2025